Triamcinolone controlled-release - EyePoint Pharmaceuticals

Drug Profile

Triamcinolone controlled-release - EyePoint Pharmaceuticals

Alternative Names: IBI-20089

Latest Information Update: 05 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Icon Bioscience
  • Developer EyePoint Pharmaceuticals; Icon Bioscience
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Diabetic macular oedema
  • No development reported Age-related macular degeneration; Retinal oedema

Most Recent Events

  • 28 Mar 2018 Icon Bioscience has been acquired by EyePoint Pharmaceuticals
  • 03 May 2016 Phase-I clinical trials in Diabetic macular oedema in USA (Intravitreous)
  • 25 Sep 2015 No recent reports on development identified - Phase-I for Retinal oedema in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top